Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.76
IRWD's Cash-to-Debt is ranked lower than
66% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.09 vs. IRWD: 0.76 )
Ranked among companies with meaningful Cash-to-Debt only.
IRWD' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.76  Med: 31.42 Max: N/A
Current: 0.76
Equity-to-Asset 0.04
IRWD's Equity-to-Asset is ranked lower than
96% of the 734 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. IRWD: 0.04 )
Ranked among companies with meaningful Equity-to-Asset only.
IRWD' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.86  Med: 0.29 Max: 0.74
Current: 0.04
-1.86
0.74
Piotroski F-Score: 4
Altman Z-Score: 0.45
Beneish M-Score: -1.86
WACC vs ROIC
10.83%
-82.75%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -34.45
IRWD's Operating Margin % is ranked lower than
80% of the 744 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.42 vs. IRWD: -34.45 )
Ranked among companies with meaningful Operating Margin % only.
IRWD' s Operating Margin % Range Over the Past 10 Years
Min: -1101.36  Med: -157.88 Max: -18.93
Current: -34.45
-1101.36
-18.93
Net Margin % -46.49
IRWD's Net Margin % is ranked lower than
82% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.16 vs. IRWD: -46.49 )
Ranked among companies with meaningful Net Margin % only.
IRWD' s Net Margin % Range Over the Past 10 Years
Min: -1192.31  Med: -164.11 Max: -29.83
Current: -46.49
-1192.31
-29.83
ROE % -184.25
IRWD's ROE % is ranked lower than
93% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.86 vs. IRWD: -184.25 )
Ranked among companies with meaningful ROE % only.
IRWD' s ROE % Range Over the Past 10 Years
Min: -299.34  Med: -128.16 Max: -48.14
Current: -184.25
-299.34
-48.14
ROA % -17.54
IRWD's ROA % is ranked lower than
78% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.49 vs. IRWD: -17.54 )
Ranked among companies with meaningful ROA % only.
IRWD' s ROA % Range Over the Past 10 Years
Min: -107.22  Med: -35.95 Max: -12.3
Current: -17.54
-107.22
-12.3
ROC (Joel Greenblatt) % -354.32
IRWD's ROC (Joel Greenblatt) % is ranked lower than
84% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.40 vs. IRWD: -354.32 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
IRWD' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1275.86  Med: -306.95 Max: -159
Current: -354.32
-1275.86
-159
3-Year Revenue Growth Rate 112.10
IRWD's 3-Year Revenue Growth Rate is ranked higher than
99% of the 607 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.70 vs. IRWD: 112.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
IRWD' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -9.3 Max: 112.1
Current: 112.1
0
112.1
3-Year EBITDA Growth Rate -52.90
IRWD's 3-Year EBITDA Growth Rate is ranked lower than
98% of the 583 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.40 vs. IRWD: -52.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
IRWD' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -7.6 Max: 51.9
Current: -52.9
0
51.9
3-Year EPS without NRI Growth Rate -38.00
IRWD's 3-Year EPS without NRI Growth Rate is ranked lower than
90% of the 551 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. IRWD: -38.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
IRWD' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -38 Max: 54.1
Current: -38
0
54.1
GuruFocus has detected 6 Warning Signs with Ironwood Pharmaceuticals Inc $IRWD.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» IRWD's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

IRWD Guru Trades in Q2 2016

Joel Greenblatt 133,821 sh (New)
Paul Tudor Jones 34,118 sh (+142.94%)
Ken Fisher 242,450 sh (+2.87%)
Vanguard Health Care Fund 4,522,387 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund Sold Out
Steven Cohen 1,167,183 sh (-1.13%)
» More
Q3 2016

IRWD Guru Trades in Q3 2016

Joel Greenblatt 147,976 sh (+10.58%)
Vanguard Health Care Fund 4,522,387 sh (unchged)
Ken Fisher 242,450 sh (unchged)
Paul Tudor Jones 30,489 sh (-10.64%)
Steven Cohen 953,927 sh (-18.27%)
» More
Q4 2016

IRWD Guru Trades in Q4 2016

Vanguard Health Care Fund 4,533,887 sh (+0.25%)
Paul Tudor Jones 28,674 sh (-5.95%)
Joel Greenblatt 131,163 sh (-11.36%)
Ken Fisher 202,850 sh (-16.33%)
Steven Cohen 291,532 sh (-69.44%)
» More
Q1 2017

IRWD Guru Trades in Q1 2017

Jim Simons 186,453 sh (New)
Steven Cohen 1,628,018 sh (+458.44%)
Joel Greenblatt 363,051 sh (+176.79%)
Vanguard Health Care Fund 4,586,087 sh (+1.15%)
Ken Fisher 202,850 sh (unchged)
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with IRWD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NAS:MDCO, NAS:ENDP, NAS:OPK, OTCPK:EVTCY, NAS:PCRX, NAS:SUPN, NAS:HZNP, NAS:RDUS, NAS:AKRX, NAS:PAHC, NYSE:TARO, NYSE:MNK, NYSE:DPLO, NAS:EGRX, NAS:IPXL, NAS:MNTA, OTCPK:KHTRF, NYSE:VRX, NYSE:CTLT, OTCPK:STDAF » details
Traded in other countries:I76.Germany,
Headquarter Location:USA
Ironwood Pharmaceuticals Inc is commercial biotechnology company. It discovers, develops and commercializes differentiated medicines that improve patient's lives.

Ironwood Pharmaceuticals is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing innovative product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Ratios

vs
industry
vs
history
PB Ratio 93.10
IRWD's PB Ratio is ranked lower than
98% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.03 vs. IRWD: 93.10 )
Ranked among companies with meaningful PB Ratio only.
IRWD' s PB Ratio Range Over the Past 10 Years
Min: 5.45  Med: 12.5 Max: 95.35
Current: 93.1
5.45
95.35
PS Ratio 10.45
IRWD's PS Ratio is ranked lower than
80% of the 721 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. IRWD: 10.45 )
Ranked among companies with meaningful PS Ratio only.
IRWD' s PS Ratio Range Over the Past 10 Years
Min: 3.5  Med: 17.77 Max: 75.81
Current: 10.45
3.5
75.81
EV-to-EBIT -34.61
IRWD's EV-to-EBIT is ranked lower than
99.99% of the 776 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.99 vs. IRWD: -34.61 )
Ranked among companies with meaningful EV-to-EBIT only.
IRWD' s EV-to-EBIT Range Over the Past 10 Years
Min: -60.5  Med: -13.25 Max: -4.2
Current: -34.61
-60.5
-4.2
EV-to-EBITDA -40.34
IRWD's EV-to-EBITDA is ranked lower than
99.99% of the 797 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.26 vs. IRWD: -40.34 )
Ranked among companies with meaningful EV-to-EBITDA only.
IRWD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -88.3  Med: -14.9 Max: -4.4
Current: -40.34
-88.3
-4.4
Current Ratio 4.54
IRWD's Current Ratio is ranked higher than
71% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.55 vs. IRWD: 4.54 )
Ranked among companies with meaningful Current Ratio only.
IRWD' s Current Ratio Range Over the Past 10 Years
Min: 2.33  Med: 4.48 Max: 9.64
Current: 4.54
2.33
9.64
Quick Ratio 4.52
IRWD's Quick Ratio is ranked higher than
75% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.85 vs. IRWD: 4.52 )
Ranked among companies with meaningful Quick Ratio only.
IRWD' s Quick Ratio Range Over the Past 10 Years
Min: 2.33  Med: 4.43 Max: 9.04
Current: 4.52
2.33
9.04
Days Inventory 68.29
IRWD's Days Inventory is ranked higher than
90% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.29 vs. IRWD: 68.29 )
Ranked among companies with meaningful Days Inventory only.
IRWD' s Days Inventory Range Over the Past 10 Years
Min: 51.22  Med: 193.31 Max: 1266.91
Current: 68.29
51.22
1266.91
Days Sales Outstanding 1.62
IRWD's Days Sales Outstanding is ranked higher than
99% of the 636 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.05 vs. IRWD: 1.62 )
Ranked among companies with meaningful Days Sales Outstanding only.
IRWD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.05  Med: 7.61 Max: 889.76
Current: 1.62
0.05
889.76
Days Payable 2.00
IRWD's Days Payable is ranked lower than
97% of the 586 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.53 vs. IRWD: 2.00 )
Ranked among companies with meaningful Days Payable only.
IRWD' s Days Payable Range Over the Past 10 Years
Min: 2  Med: 513.78 Max: 8217.61
Current: 2
2
8217.61

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -6.50
IRWD's 3-Year Average Share Buyback Ratio is ranked lower than
58% of the 442 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.30 vs. IRWD: -6.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
IRWD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -144.5  Med: -9.9 Max: 0
Current: -6.5
-144.5
0

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.59
IRWD's Price-to-Median-PS-Value is ranked higher than
92% of the 645 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. IRWD: 0.59 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
IRWD' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.23  Med: 1.02 Max: 3.52
Current: 0.59
0.23
3.52
Earnings Yield (Greenblatt) % -2.89
IRWD's Earnings Yield (Greenblatt) % is ranked lower than
74% of the 1046 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.36 vs. IRWD: -2.89 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
IRWD' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -3.23  Med: 0 Max: 46.78
Current: -2.89
-3.23
46.78

More Statistics

Revenue (TTM) (Mil) $260.1
EPS (TTM) $ -0.83
Beta1.44
Short Percentage of Float18.01%
52-Week Range $12.03 - 19.39
Shares Outstanding (Mil)148.62

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 288 417 557
EPS ($) -0.82 -0.19 0.69
EPS without NRI ($) -0.82 -0.19 0.69
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for IRWD

Headlines

Articles On GuruFocus.com
What Do the Ardelyx Numbers Mean for the Company? May 15 2017 
Allergan and Ironwood Launch Campaign Designed to Empower the Nearly 64 Million Americans Estimated Apr 13 2017 
Ken Fisher's Best Investments: Credicorp, Ambev, Tata Motors Jul 11 2016 
A Look at Steven Cohen's Investment in Ironwood Pharmaceuticals Aug 25 2015 
Weekly 3-Year Low Highlight: EXC, RVBD, IRWD, SHOS Oct 27 2013 
Five-Year Lows: Singapore Airlines Limited, Gold Field Ltd., Ironwood Pharmaceuticals Inc., Northwes Oct 22 2013 
Weekly CEO Buys Highlight: GDOT, VOCS, PES, IRWD, ABR Nov 11 2012 
Edward Owens Made Few Purchases In Times of Changes: Boston Scientific Corp., Ironwood Pharmaceutica May 10 2010 
Vanguard Health Care Fund Buys Ironwood Pharmaceuticals Inc., Johnson & Johnson, Boston Scientific C May 06 2010 

More From Other Websites
Allergan's Irritable Bowel Drug Viberzi Approved in Canada May 17 2017
Edited Transcript of IRWD earnings conference call or presentation 8-May-17 12:30pm GMT May 12 2017
Ironwood Pharmaceuticals, Inc. – Value Analysis (NASDAQ:IRWD) : May 11, 2017 May 11 2017
Ironwood Pharmaceuticals to Present at the Bank of America Merrill Lynch Healthcare Conference May 10 2017
Ironwood Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : IRWD-US :... May 10 2017
Ironwood Pharmaceuticals Presents Data Further Elucidating Linaclotide’s Effect on Pain at... May 09 2017
Ironwood (IRWD) Q1 Loss Wider than Expected, Sales Miss May 09 2017
Ironwood reports 1Q loss May 08 2017
Ironwood Pharmaceuticals Provides First Quarter 2017 Investor Update May 08 2017
Investor Network: Ironwood Pharmaceuticals, Inc. to Host Earnings Call May 08 2017
Ironwood Pharmaceuticals to Present New Data for Linaclotide, Linaclotide Delayed Release and... May 01 2017
Ironwood Pharmaceuticals to Host First Quarter 2017 Investor Update Call Apr 24 2017
Are Options Traders Betting on a Big Move in Ironwood Pharmaceuticals (IRWD) Stock? Apr 18 2017
Allergan and Ironwood Launch Campaign Designed to Empower the Nearly 64 Million Americans Estimated... Apr 13 2017
Ironwood Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : IRWD-US :... Apr 06 2017
Ironwood Pharmaceuticals Appoints Dr. Christopher Wright as Senior Vice President of Global... Apr 06 2017
ETFs with exposure to Ironwood Pharmaceuticals, Inc. : April 5, 2017 Apr 05 2017
Ironwood Pharmaceuticals, Inc. :IRWD-US: Earnings Analysis: Q4, 2016 By the Numbers : March 17, 2017 Mar 17 2017
Ironwood Pharmaceuticals, Inc. :IRWD-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017 Mar 14 2017
Synergy Pharmaceuticals: Approval, Now What? Mar 13 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)